Lifeblood Medical, Inc. Receives Notice of Allowance for U.S. Patent

Published: Mar 28, 2007

ADELPHIA, N.J., March 28 /PRNewswire/ -- Lifeblood Medical, Inc. is pleased to announce that it has received a Notice of Allowance from the U.S. Patent Office for its patent application titled, "Composition for Maintaining Organ and Cell Viability." The allowed claim provides patent protection for Lifeblood's proprietary solutions related to the prolonged preservation of organs, tissues and cells, and particularly for the preservation of organs donated for transplantation, as well as methods of making and using the same.

"We are extremely pleased with the allowance of our first patent," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical, Inc. "This patent, once issued, will provide Lifeblood with significant intellectual property protection to support Lifor(R) for FDA approval for heart preservation and transportation. We also have additional pending U.S. patent applications directed to other aspects of the technology including related compositions, method of making and using the proprietary solutions and the Lifor(R) technology for preservation and transportation of a multitude of organs, cells and tissues."

About Lifeblood Medical, Inc.

Lifeblood Medical, Inc., headquartered in Adelphia N.J., is a cell culture/biotech company whose goal is to enhance and extend the quality of life in the field of organ, cell and tissue preservation through the utilization of our proprietary solutions and by providing key reagents to the research community.

We distribute high quality serum and reagents to the research community at competitive prices. Our products include Serum, Serum Enhancers, Antibiotics and Specialty Media.

Our proprietary solution is considered platform enabling technology, with the potential to address a multitude of applications through all segments of the tissue, cell and organ transplant markets by way of its unique serum free, animal protein free and oxygen carrying properties. For the cell and tissue preservation market we offer LiforCell(R). For whole organ preservation, transportation and transplantation we offer LIFOR(R). LIFOR(R) is currently undergoing clinical trials for the support of heart and kidney harvesting, transporting and reimplantation. FDA submission is anticipated later this year. Additional information is available online at

Lifeblood Medical, Inc.

CONTACT: Joseph Fischer of Lifeblood Medical, Inc., +1-732-431-5833

Back to news